Neurocrine Biosciences (NBIX) Stock Forecast & Price Target

Neurocrine Biosciences Inc. is positioned for significant revenue growth driven by its lead product, Ingrezza, which is projected to achieve sales of around $3 billion by 2028, with a potential upside reaching approximately $3.5 billion under favorable conditions. Additionally, the company's emerging product, Crenessity, for congenital adrenal hyperplasia, is expected to generate peak revenues exceeding $1 billion by 2030. Furthermore, Neurocrine's robust pipeline, featuring late-stage assets in major depressive disorder and early-stage products in central nervous system indications, supports a compelling long-term growth outlook.

Neurocrine Biosciences faces significant competition risks that may impede the growth of its leading product, INGREZZA, in the tardive dyskinesia (TD) market, as market penetration efforts may slow down. Additionally, the Huntington's disease chorea (HDChorea) market is limited and already served by two approved products, limiting opportunities for substantial revenue growth in this segment. Furthermore, in the congenital adrenal hyperplasia (CAH) space, Neurocrine's Crenessity could encounter competitive pressures from other emerging therapies, such as atumelnant from Crinetics Pharmaceuticals, further challenging its market position.